Shenlian Biotech released its 2026 interim report, showing total operating revenue of 112 million yuan, down 8.05 percent year on year. Net profit attributable to the parent company was a loss of 19.1464 million yuan, with the loss widening by 6.2767 million yuan compared with the same period last year. Net cash flow from operating activities was negative 64.6641 million yuan, a year-on-year decrease of 25.2751 million yuan. The company's asset-liability ratio was 9.85 percent, gross margin was 57.36 percent, return on equity was negative 1.38 percent, and diluted earnings per share was negative 0.05 yuan. The number of shareholders was 9,297, and the top ten shareholders held 55.79 percent of the total share capital.
Shanghai Shen Lian Biomedical CorpNet loss widened to 19.1464 million yuan with revenue down 8.05%.
